Clinical trials: sponsored by Henan Cancer Hospital
Breast Cancer
Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer
The goal of this clinical trial is to learn if serplulimab is effective in early HR+/HER2- breast cancer. It will also learn about the safety of serplulimab.
- Trial name
- NCT06394661
- Testing
- Serplulimab+NabPE
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Henan Cancer Hospital
TNBC - Triple-Negative Breast Cancer
SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer
This is a prospective, open-label, multicenter Phase II study evaluating the efficacy and safety of of SHR-A2102 in combination with Adebrelimab in Early Triple-Negative Breast Cancer(TNBC)
- Trial name
- NCT06819319
- Testing
- SHR-A2102 ; Adebrelimab injection
- Volunteers
- 52 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
The goal of this clinical trial is to evaluate the efficacy and safety of SHR-A1811 plus pertuzumab in combination with or without albumin-paclitaxel neoadjuvant therapy for early or locally advanced HER2-positive breast cancer.
- Trial name
- NCT06927180
- Testing
- SHR-A1811, Pertuzumab, Albumin-Paclitaxel
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer Invasive
NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
The goal of this clinical study is to learn if serplulimab is effective in early HR+/HER2- breast cancer. This trial serves a prospective parallel control cohort for HELEN-018 (NCT).
- Trial name
- NCT06781281
- Testing
- Serplulimab, NabPE
- Where
- China
- Volunteers
- 709 people
- Sponsor
- Henan Cancer Hospital
Lung Cancer
Organoid-guided Personalized Treatment of Pleural Effusion
The study is a single-arm, single-center clinical research that utilizes patient-derived tumor organoids to predict drug sensitivity, thereby assisting clinicians in formulating treatment plans to benefit lung cancer patients…
- Trial name
- NCT06959173
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Solid Tumors
Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors
The purpose of this study is to observe and evaluate the efficacy and safety of HRS-4642 combined with SHR-A2102 in the treatment of advanced solid tumors
- Trial name
- NCT06955390
- Testing
- SHR-A2102+HRS-4642
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Henan Cancer Hospital
NSCLC
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
EGFR mutation-positive NSCLC patients have a higher risk of developing brain metastases. The prognosis is poor for patients presenting with brain or leptomeningeal metastases at any stage, particularly those with such metastases…
- Trial name
- NCT06945705
- Testing
- furmonertinib combined with anlotinib
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Henan Cancer Hospital
Diffuse Large B Cell Lymphoma, CD79A Gene Mutation
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of zanubrutinib combined with standard chemotherapy in the treatment for patients with diffuse large B cell lymphoma and…
- Conditions
- Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation
- Trial name
- NCT04668365
- Testing
- Rituximab, Zanubrutinib, Cyclophosphamide
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Henan Cancer Hospital
Primary Central Nervous System Lymphoma
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of Rituximab, Lenalidomide combined with high-dose Methotrexate and Temozolomide (RL-MT) in the first-line treatment for…
- Trial name
- NCT04737889
- Testing
- Rituximab, Lenalidomide, Methotrexate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Lymphoma, Gene Abnormality
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
- Trial name
- NCT04263935
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Henan Cancer Hospital
Central Nervous System Lymphoma
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
This is a prospective single arm, phase II clinical trial to observe the efficacy and safety of orelabrutinib combined with pemetrexed in the treatment for patients with relapsed/refractory central nervous system lymphoma.
- Trial name
- NCT05209620
- Testing
- ICP-022, Pemetrexed
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Advanced or Metastatic Breast Cancer
The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer
The incidence of oral mucositis associated with TROP2-ADC therapy in patients with advanced breast cancer is notably high. Identifying effective preventive and therapeutic strategies is essential for enhancing patient quality of…
- Trial name
- NCT06934733
- Testing
- Oral cryotherapy, Routine oral care
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Henan Cancer Hospital
Opioid-Induced Constipation, Pain Cancer
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
This study is a prospective, single-arm, multicenter, real-world study to evaluate effect of bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain.
- Trial name
- NCT06897917
- Testing
- Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer, Locally Advanced or Metastatic Breast Cancer
A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients
This study is being conducted to evaluate the efficacy and safety of SHR-A1811 and Fulvestrant in Combination with or without HS-10352 in locally advanced or metastatic breast cancer patients.
- Trial name
- NCT06788197
- Testing
- SHR-A1811+ Fulvestrant, SHR-A1811+ Fulvestrant+HS-10352
- Volunteers
- 52 people
- Sponsor
- Henan Cancer Hospital
Esophageal Malignant Neoplasm Primary
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
A prospective trial design was used to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1/PD-L1 inhibitors in the treatment of locally advanced resectable esophageal squamous cell carcinoma.
- Trial name
- LA-ESCC (NCT06888531)
- Testing
- Neoadjuvant chemoradiotherapy combined with PD-1/PD-L1 inhibitors for the treatment of locally advanced resectable esophageal squamous cell carcinoma
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer, HER2-positive Breast Cancer
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
At present, the incidence rate of breast cancer has exceeded that of lung cancer, becoming the largest cancer in the world. HER2 overexpression breast cancer accounts for about 20%~30% of all breast cancer patients.
- Trial name
- NCT05918328
- Testing
- Albumin paclitaxel+trastuzumab+pyrrolitinib, Docetaxel+Carboplatin+trastuzumab+Parstuzumab
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer, Leptomeningeal Metastasis
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
The primary objective of this clinical study is to evaluate the efficacy of high-dose furmonertinib combined with bevacizumab and pemetrexed (triple therapy) in the treatment of non-small cell lung cancer (NSCLC) with…
- Conditions
- Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation
- Trial name
- NCT06643000
- Testing
- furmonertinib
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Esophageal Cancer, Neoadjuvant Therapy
Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI
This study aims to predict the efficacy of different types of neoadjuvant therapy and related postoperative pathological indicators in patients with esophageal cancer based on imaging parameters from CT and multimodal MRI, as…
- Trial name
- NCT06833775
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
Esophageal Cancer
Mechanistic Study on the Diagnosis of Esophageal Cancer Lymph Node Metastasis Using Spectral CT, Multimodal MRI, FAPI PET-CT, Pathology, and AI Evaluation System
The objective of this study is to address the urgent issues in the diagnosis of lymph node metastasis in esophageal cancer. By employing multimodal MRI, spectral CT imaging and FAPI PET-CTtechniques, the study will correlate…
- Trial name
- NCT06818214
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Henan Cancer Hospital
SCLC, Extensive Stage
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
This study hypothesizes that nanocrystalline megestrol acetate can improve the cachexia condition in patients and enhance the efficacy of immunochemotherapy regimens.
- Trial name
- NCT06793228
- Testing
- Nanocrystalline Megestrol Acetate, Tislelizumab, PTOC
- Where
- 4 sites in China
- Volunteers
- 250 people
- Sponsor
- Henan Cancer Hospital